Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?
Julita Anna KrahelAnna BaranTomasz W KamińskiIwona FlisiakPublished in: International journal of molecular sciences (2020)
Psoriasis is a systemic, immune-metabolic disease with strong genetic predispositions and autoimmune pathogenic traits. During psoriasis progression, a wide spectrum of comorbidities comes into play with the leading role of the cardio-metabolic syndrome (CMS) that occurs with the frequency of 30-50% amongst the psoriatic patients. Both conditions-psoriasis and CMS-have numerous common pathways, mainly related to proinflammatory pathways and cytokine profiles. Surprisingly, despite the years of research, the exact pathways linking the occurrence of CMS in the psoriasis population are still not fully understood. Recently published papers, both clinical and based on the basic science, shed new light into this relationship providing an insight into novel key-players proteins with plausible effects on above-mentioned interplay. Taking into account recent advances in this important medical matter, this review aims to discuss comprehensively the role of four proteins: proprotein convertase subtilisin/kexin type-9 (PSCK9), angiopoietin-like protein 8 (ANGPLT8), sortilin (SORT1), and cholesteryl ester transfer proteins (CEPT) as plausible links between psoriasis and CMS.
Keyphrases
- metabolic syndrome
- rheumatoid arthritis
- atopic dermatitis
- ejection fraction
- newly diagnosed
- end stage renal disease
- healthcare
- public health
- disease activity
- multiple sclerosis
- low density lipoprotein
- gene expression
- systemic lupus erythematosus
- systematic review
- type diabetes
- randomized controlled trial
- copy number
- dna methylation
- uric acid
- drug induced
- skeletal muscle
- amino acid
- hidradenitis suppurativa